# Efficacy and Safety of Belimumab in SLE Patients

> **NCT04515719** · PHASE4 · COMPLETED · sponsor: **RenJi Hospital** · enrollment: 231 (actual)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** Belimumab
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04515719
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-10
- **Primary completion:** 2022-04-10
- **Final completion:** 2022-04-10
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04515719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04515719, "Efficacy and Safety of Belimumab in SLE Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04515719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*